CMPS - Numinus Wellness: Integrated Mental Health Opportunity

• Numinus offers a lower risk exposure to the psychedelics space in comparison to stocks focused on drug discovery and development.
• Capital flows into the sector have not yet recognized the importance of the therapeutic delivery model.
• Numinus has a healthy cash balance, a solid industry reputation, and is well-placed to build out the infrastructure to capitalize on anticipated regulatory approvals.
• Whilst MAPS is making great progress towards achieving regulatory approval for MDMA-assisted therapy, investors should be mindful that this remains a high-risk sector.

For further details see: